pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

213 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT810Endpoints607BioPharma Dive231onclive165BioSpace77Fierce Biotech75raps32fda press20globenewswire health
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Preoperative Intravesical Mitomycin-C Before TURBT Cuts Recurrence Risk by 77% in NMIBC Over 5 Years
    Two doses of intravesical mitomycin-C administered before TURBT produced a 77% reduction in the risk of recurrence or death vs TURBT alone in NMIBC.
    onclive · 2mo ago↗ source
  • Genomic Disease Burden Markers, PD-L1 Expression Predictive of pOR With Neoadjuvant Gem-iDRS ± Cetrelimab in MIBC
    A biomarker analysis of SunRISe-4 found that high baseline TMB, GBD, and PD-L1 expression were associated with pathologic overall response to the regimen.
    onclive · 2mo ago↗ source
  • Dr Croll on Radiographic Size Change vs irRVT After Neoadjuvant Therapy in RCC
    Benjamin Croll, MD, discusses findings from a study of the correlation between radiographic response and pathologic response in RCC.
← prev
page 3 of 9
next →
20
fda recalls20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago
↗ source
  • FDA Approves T-DXd for Early-Stage HER2+ Breast Cancer
    The FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.
    onclive · 2mo ago↗ source
  • Dr Garzotto on Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Localized Prostate Cancer
    Mark Garzotto, MD, discusses efficacy data with aglatimagene besadenovec plus valacyclovir and EBRT in localized prostate cancer.
    onclive · 2mo ago↗ source
  • Dr Cirstea on Sequencing Considerations in R/R Multiple Myeloma
    Diana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.
    onclive · 2mo ago↗ source
  • Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBC
    Jason Hafron, MD, discusses the significance of the FDA approval of adjuvant atezolizumab for MRD+ muscle-invasive bladder cancer.
    onclive · 2mo ago↗ source
  • Durvalumab Plus BCG Reduces High-Risk NMIBC Recurrence or Death Risk by 32% in Phase 3 POTOMAC Trial
    Durvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.
    onclive · 2mo ago↗ source
  • Darolutamide Plus ADT Yields Significant OS Benefit in mHSPC
    Darolutamide plus ADT demonstrated a 50% reduction in the risk of death in metastatic hormone-sensitive prostate cancer.
    onclive · 2mo ago↗ source
  • OncLive Weekly News Quiz (5/15/2026): Did You Catch 3 New FDA Oncology Approvals?
    Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
    onclive · 2mo ago↗ source
  • Pembrolizumab Plus BCG Elicits 92% CR Rate in BCG-Naive Very High-Risk T1 NMIBC
    Pembrolizumab plus BCG achieved a 92% 6-month complete response rate in very high-risk T1 bladder cancer with no progression to muscle-invasive disease.
    onclive · 2mo ago↗ source
  • FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder Cancer
    The FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.
    onclive · 2mo ago↗ source
  • Detalimogene Voraplasmid Yields 54% CR Rate in Heavily Pretreated BCG-Unresponsive NMIBC With CIS
    TRAEs were generally reversible and low grade, and 96.8% of patients remained free from progression to T2 or greater disease at the data cutoff.
    onclive · 2mo ago↗ source
  • Roswell Park Team Members Take Part in Global Conference Dedicated to Indigenous Peoples and Cancer
    Members of Roswell Park Comprehensive Cancer Center participated in the 2026 World Indigenous Cancer Conference.
    onclive · 2mo ago↗ source
  • Poll Findings Highlight the Most Anticipated GU Cancer Abstracts at ASCO 2026
    GU experts identified key abstracts of interest from the upcoming ASCO Annual Meeting via OncLive’s social media.
    onclive · 2mo ago↗ source
  • OncLive Polls Reveal Picks for Top GI Cancer Abstracts, Areas of Interest at ASCO 2026
    Polls highlighted key abstracts of interest from the upcoming ASCO Annual Meeting.
    onclive · 2mo ago↗ source
  • Prevention and Personalization Drive the Future of Oncodermatology in Melanoma
    Beth McLellan, MD, discusses radiation dermatitis prevention, scalp cooling equity, and the future of personalized oncodermatology in melanoma management.
    onclive · 2mo ago↗ source
  • AVB-001 Encapsulated IL-2 Cell Therapy Shows Safety and Immune Activity in Platinum-Resistant HGSOC
    AVB-001 was tolerable and activated CD8+ and CD4+ T cells without regulatory T-cell expansion in platinum-resistant high-grade serous ovarian carcinoma.
    onclive · 2mo ago↗ source
  • Dr Hunter on Luspatercept and Other Treatment Options for Anemia in Myelofibrosis
    Anthony M. Hunter, MD, discusses treatment decision-making for the management of anemia in myelofibrosis.
    onclive · 2mo ago↗ source
  • Dr Jones on the Protective Benefit and Tolerability of GLP-1 Agonists vs Aspirin for CRC Prevention
    Colton Jones, MD, shares data from a retrospective analysis of GLP-1 receptor agonists vs aspirin for the primary prevention of colorectal cancer.
    onclive · 2mo ago↗ source
  • IO in NMIBC, Radioligand Therapy in mHSPC Highlight Key Presentations to Watch at AUA 2026
    Ahead of the 2026 AUA Annual Meeting, GU cancer experts highlighted the abstracts that they are anticipating the most.
    onclive · 2mo ago↗ source
  • Ibrutinib Monotherapy Yields Decade-Long Durable Efficacy in Across CLL Subtypes
    Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.
    onclive · 2mo ago↗ source
  • Imaging Clues That Raise Suspicion for Diffuse Midline Glioma
    n this episode, Dr. Chong sets up the clinical reality that patients usually present with imaging before tissue and asks Dr. Shonka how MRI findings should shape suspicion for DMG.
    onclive · 2mo ago↗ source
  • Two Diseases That Share a Name — Defining Glioblastoma and Diffuse Midline Glioma Under the 2021 WHO Classification
    In this opening episode, Dr. Shonka and Dr. Chong frame the conversation around two diseases that share the name glioma but differ fundamentally in biology, demographics, and treatment.
    onclive · 2mo ago↗ source
  • Evolving Strategies for Myelofibrosis-Associated Anemia Highlight Persistent Gaps in Biomarker Guidance
    Aaron Gerds, MD, MS, and Anthony M. Hunter, MD, break down the challenges of anemia management in myelofibrosis and potential treatment avenues.
    onclive · 2mo ago↗ source